The Regional Health Secretariat of Madeira, in collaboration with Novartis, will launch a pioneering programme that aims to reduce the impact of cerebro-cardiovascular diseases (CVD) and contribute to healthier longevity.
This programme, whose cooperation protocol was signed today, “is based on three pillars: Data Intelligence, Technological Innovation combined with Therapeutic Innovation, and the creation of an Advanced Cardiovascular Longevity Unit.”
In a press statement, the Regional Secretary for Health and Civil Protection, Pedro Ramos said:
“This partnership is an example of promoting the collaborative culture that we want to encourage in the region, through multisectoral cooperation, dissemination, application, and transfer of knowledge in the field of longevity. It will allow us to maintain the downward trend in CVD mortality in the Autonomous Region of Madeira and reverse the growing trend in mortality from ischemic heart disease and other heart diseases, with a clear benefit for our population and economy.”
Simon Gineste, the president of Novartis in Portugal, also adds that the company makes its “transformative innovation” and knowledge available to “reverse the negative impact of the disease. The challenge of longevity is to ensure an intervention throughout the life cycle that allows for the maintenance of the highest level of functional capacity of the population, modifying behaviours and creating the conditions for the prevention, rapid identification, management, and treatment of the diseases that most affect us as a society.”
Samantha Gannon
info at madeira-weekly.com
